An observational study in Ulcerative Colitis, Crohn Disease and Obesity, sponsored by Viome. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by Viome · Observational
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and remissions, or progression of their disease.
This is a longitudinal, observational study whose main goal is to identify the human and microbial determinants of gastrointestinal diseases. Molecular and metadata will be collected from a large study population at multiple time points. Machine learning will be applied to all data, and models will be evaluated for development of novel diagnostic and therapeutic tools.
1,853 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
This study's enrollment of 17 is below the median of 198 across 551 observational studies indexed under Colitis, Ulcerative.
Browse Colitis, Ulcerative studies →Viome is the lead sponsor of 25 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients 18 years old or older who visit WAGI for the following reasons:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with ulcerative colitis.
Participants with Crohn's disease.
Participants that are obese.
Participants with colon polyps.
Participants with Eosinophilic esophagitis
Participants with Gastroesophageal Reflux Disease (GERD).
Participants with gastritis.
Participants with gastric ulcers.
Participants with duodenal ulcers.
Participants with intestinal metaplasia (risk factor for esophageal cancer).
Participants with gastric cancer.
Participants with Lymphocytic/Microscopic Colitis.
Participants with Celiac Sprue.
Participants with IBS.
Participants with SIBO.
Participants with NAFLD.
Participants with Gallstone disease.
Identification of human determinants of gastrointestinal diseases.
Identification of biomarkers that indicate gastrointestinal diseases.
Time frame: Up to 10 years
Identification of microbial determinants of gastrointestinal diseases.
Identification of microbial species that indicate gastrointestinal disease.
Time frame: Up to 10 years
Prediction of efficacy of biologics in treating IBD.
Prediction of the efficacy of a biologic medication against IBD based on molecular data and metadata.
Time frame: Up to 10 years.
Development of a molecular test for C. difficile infection (CDI)
Development of a molecular test for C. difficile infection (CDI)
Time frame: Up to 10 years.
Quantify change in microbial species over time post colonoscopy
Quantification of changes observed in the microbiome post colonoscopy.
Time frame: Up to 10 years.
Ran from Nov 2022 to primary completion in Nov 2023, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.